Please select the eligibility criteria that correspond to the clinical trial below.
Title: Clinical Effect and Tolerability of Atorvastatin Versus Placebo in Patients With Pulmonary Hypertension: Double-blinded, Randomised, Prospective Phase II Study for 6 Months With Adjusted Doses of Atorvastatin
Brief Summary: Clinical effect and tolerability of atorvastatin versus placebo in patients with Pulmonary Hypertension: double-blinded, randomised, prospective phase II study for 6 months with adjusted doses of Atorvastatin


Options:
A: Inclusion Criteria:

* Statin-naive (i.e., has never taken statins before)

Exclusion Criteria:

* Previous use of statins
* Current treatment with cholesterol- or triglyceride-lowering drugs
* Impaired liver or kidney function
* Untreated hypothyroidism or hyperthyroidism
* Treatment with other medications known to increase risk of myopathy in atorvastatin-treated patients (e.g., cyclosporine, azithromycin, erythromycin, azole antifungals, fusidic acid)
* Existing infection requiring treatment with antibiotic therapy
* Consumption of greater that 1 quart of grapefruit juice per day
* Documented history of neuroleptic malignant syndrome
* Inherited muscle disorders or myopathy
* Known sickle cell trait
* Cancer within the 5 years prior to study entry
* Diabetes
* Currently being treated for high blood pressure
* Coronary artery disease
* Peripheral vascular disease
* Physical disability or previous injury that prevents safe exercise testing
* Pregnant or breastfeeding
B: Inclusion Criteria:

* Diabetes mellitus treated with insulin or orl agents
* At least 50 years old

Exclusion Criteria:

* Previous cardiovascular events
* current or past (within last 30 days) treatment with aspirin
* current or past (within last 180 days) treatment with statins
C: Inclusion Criteria:

* hypercholesterolemia

Exclusion Criteria:

* chronic renal disease
D: Inclusion Criteria:

* Able to understand and willing to sign the informed consent form
* \<=65 and \>=18years old
* Diagnosis of pulmonary arterial hypertension (Mean pulmonary artery pressure greater than 25 mm Hg at rest with a pulmonary capillary wedge pressure less than 15 mm Hg )that is a) idiopathic, b) familial, or c) associated with connective-tissue disease, d)congenital systemic-to-pulmonary shunt occurring after surgical/interventional repair that had been performed at least five years previously or in the absence of indications for surgery/intervention treatment e) chronic thromboembolism PAH in the absence of indications for surgery
* Patients in WHO functional class II to III
* Vasodilator Testing nonresponders
* Baseline six-minute walking distance between 100 and 460 m

Exclusion Criteria:

* PAH related to other etiologies (Groups 2, 3 and 5 pulmonary hypertension)
* A forced expiratory volume in one second/ forced vital capacity bellow 50% or a total lung capacity of less than 60 percent predicted value
* A 6-minute walk distance of less than 100 or more than 460 m
* A positive acute vasodilator response
* Current treatment with calcium-channel blockers or specific therapy (endothelin receptor antagonist, phosphodiesterase-5 inhibitor, or prostacyclin)
* Inability to perform 6-minute walk test
* Serum transaminase level three times above the upper limit of normal
* Creatine kinase level five times above the upper limit of normal
* Previously diagnosed heart disease such as serious cardiac arrhythmias, unstable angina pectoris, myocardial infarction
* History of transient ischemia attack or stroke within three months
* Bleeding disorder
* Positive pregnancy test or breastfeeding practice
* History or suspicion of inability to cooperate

Answer: D